Automating Routine Analysis of Therapeutic mAbs in High Volume Applications

Register Free:https://www.biopharminternational.com/bp/mABs

Event Overview:

Join Waters and Genovis for an in-depth look at methods and workflows designed to automate automate routine analysis of therapeutic mAbs in high volume applications.

Developing and manufacturing of therapeutic mAbs requires analysis of many different critical quality attributes (CQAs) such as Fc glycosylation, oxidation, C-terminal lysine clipping, glycation among others. High-volume applications like clone selection, process development and stability studies generate many samples to be analyzed. This creates a bottleneck which can slow down the development of new therapeutics and causes a demand for less manual labor in the sample preparation and analysis than the standard peptide mapping approaches used for characterization would allow for.

Key Learning Objectives:

• How to accelerate therapeutic mAbs workflows by automating analysis of critical quality attributes (CQAs)
• How to use an automated method that provides a reproducible profile of N-glycans released from human chorionic gonadotrophin (hCG)
• How to automate Protein A purification to be able to analyze CQAs of mAbs directly from complex samples such as harvested cell culture fluid

Who Should Attend:

Biopharmaceutical lab scientists and bench scientists working with, or doing research on, therapeutic mAbs and complex proteins.

Speakers

Yamin Htet, PhD
Senior Scientist
Waters

A Chemist by training, Yamin has received her undergraduate and masters degrees in chemistry from Furman University and earned her doctorate from Clemson University. Her diverse research experience spans the synthesis of catalysts to drug screening via DNA-Encoded Libraries (DEL) technologies. At Waters, Yamin’s work focuses on developing new sample preparation chemistries for biopharmaceuticals.

Jonathan Sjögren, PhD
VP Business Development
Genovis

Dr. Jonathan Sjögren holds a PhD in Experimental Infection Medicine and a Master’s degree in Biotechnology Engineering, both from Lund University. He is a specialist in enzymes with immunomodulating activities from pathogenic bacteria including proteases and glycosidases with activities on antibodies and other biopharmaceuticals. Following his discovery and commercialization of the endoglycosidase EndoS2, Jonathan has been involved in launching novel enzymes for use in analytical workflows within the biopharmaceutical industry.

Register Free: https://www.biopharminternational.com/bp/mABs